Eyenovia Inc. (NASDAQ: EYEN)

Introduction

Eyenovia, Inc. (NASDAQ: EYEN; Korean name: 아이노비아) is an ophthalmic technology company headquartered in New York, New York. The company develops and commercializes eye-care products using its proprietary Optejet® topical ophthalmic medication dispensing platform. Eyenovia's shares trade on the NASDAQ exchange under the ticker EYEN.

Corporate Structure

• Exchange: NASDAQ (NAS)
• Ticker: EYEN
• Founded: 2014
• Headquarters: New York, New York
• Company size: 51–200 employees
• Industry: Pharmaceutical Manufacturing, Ophthalmology

Significant shareholders (Schedule 13D, May 15, 2025):

• Avenue Venture Opportunities Fund, L.P. – 2,393,199 shares (27.2%) via $4.0 million convertible loan at $1.68/share
• Avenue Venture Opportunities Fund II, L.P. – 3,589,799 shares (40.7%) via $6.0 million convertible loan at $1.68/share

Combined, these funds hold 67.9% of outstanding shares, indicating a potential influence on governance and financing.

Recent Developments

Stock Performance (May 22, 2025)

• Closing price: $1.8050 (up 28.93%)
• Volume: 2,019,452 shares
• 52-week range: $0.85–$124.80

Reverse Merger LOI (March 20, 2025)

Eyenovia entered a non-binding Letter of Intent with Betaliq, Inc. to pursue a potential reverse merger.

• Valuation assumption at closing: Betaliq $77 million; Eyenovia $15 million
• Ownership split: Betaliq holders 83.7%; Eyenovia holders 16.3%
• The transaction aims to combine Betaliq's EyeSol® water-free delivery for glaucoma with Eyenovia's Optejet platform
• Subject to due diligence, definitive agreements, board approvals, and financing contingencies

SEC Filings (May 19, 2025)

• Form 8-K: Reports on material events under Items 2.02 and 9.01
• Form 10-Q: Quarterly report for the period ended March 31, 2025 (detailed financials not disclosed in summary)

Product and Advisory Board Activity

• November 8, 2024: Phase 4 MydCombi® study presented at AAOpt 2024 in Indianapolis
• 2024 Advisory Boards (AAO, AAOpt): Discussions on Clobetasol Propionate 0.05% and MydCombi®
• Clobetasol launch communications to US eye-care physicians via LinkedIn posts (late 2024–early 2025)

Pipeline and Strategic Focus

• Optejet® device for front-of-the-eye conditions: presbyopia, pediatric myopia, mydriasis, dry eye disease
• Dry eye candidates: EYEN-510 (cyclosporine), EYEN-520 (fonadlepar), EYEN-530 (clobetasol propionate)
• US addressable dry eye market: $5.5 billion
• Planned US regulatory submission for user-filled Optejet in Q4 2025

Financial and Strategic Analysis

Metric	Value	Source (Date)
Market Capitalization	$5.187 million	Yahoo Finance (May 22, 2025)
Enterprise Value	$11.25 million	Yahoo Finance
Price/Sales (TTM)	25.77	Yahoo Finance
EPS (TTM)	–42.65	Yahoo Finance
Cash and Equivalents	$2.12 million	Yahoo Finance
Convertible Debt	$10 million	Schedule 13D (May 15, 2025)
1-Year Target Estimate	$2.00	Yahoo Finance

• The negative trailing EPS and the high EV/revenue ratio indicate ongoing investment in research and development with limited revenue generation.
• The convertible loans and proposed merger reflect efforts to secure capital and expand technological capabilities.

Market Position and Industry Context

Eyenovia operates in the ophthalmic pharmaceuticals and drug-delivery device sector. Its Optejet® platform competes with conventional eye-drop formulations and emerging technologies like Betaliq's EyeSol®. Key focus areas include:

• Dry eye disease (US market $5.5 billion)
• Glaucoma
• Presbyopia and myopia control
• Postoperative inflammation and mydriasis

Strategic partnerships with SGN Nanopharma, Senju, and Formosa Pharmaceuticals support the development of combination products, positioning Eyenovia within a specialized niche of ophthalmic therapeutics.

tl;dr

• EYEN closed at $1.8050 on May 22, 2025, up 28.93% (vol. 2,019,452).
• March 20, 2025: non-binding LOI to merge with Betaliq, combining EyeSol® and Optejet® technologies; proposed valuations of $77 million (Betaliq) and $15 million (Eyenovia).
• Schedule 13D (May 15, 2025) reports 67.9% ownership by Avenue Venture funds via $10 million convertible debt.
• Regulatory submission for user-filled Optejet targeted for Q4 2025; dry eye pipeline addresses a $5.5 billion US market.
• Analyst 1-year price target: $2.00; financials indicate continued R&D spending and a high EV/revenue ratio.